Risks of intravenous immunoglobulin in sepsis affect trial design.
Sujoy
S
Khan
W A C
WA
Sewell
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000328:Adult; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D018805:Sepsis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous